Embracing the new budget caps the U.S. Congress approved last week, the Trump administration released a fiscal 2019 budget proposal Monday that's generous to the FDA and the opioid fight, but once again short on love for the NIH. Read More
Aveo Oncology Inc., of Cambridge, Mass., and Eusa Pharma Inc., of Hemel Hempstead, U.K., reported preliminary results of the phase II portion of the TiNivo phase Ib/II trial testing Fotivda (tivozanib), a vascular endothelial growth factor tyrosine kinase inhibitor, in combination with PD-1 inhibitor Opdivo (nivolumab, Bristol-Myers Squibb Co.) in patients with metastatic renal cell carcinoma at the 2018 American Society of Clinical Oncology's Genitourinary Cancers Symposium. Read More
Ziopharm Oncology Inc., of Boston, disclosed data demonstrating point-of-care manufacturing of human T cells expressing chimeric antigen receptor (CAR) that persist and have an anti-tumor effect in preclinical models were presented at the Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond in Keystone, Colo. Read More
DUBLIN – Shares in Poxel SA rose as much as 32 percent Monday on the back of a partnering deal with Roivant Sciences GmbH, in which it is getting $35 million up front, $15 million in equity investment and potentially $600 million in development, regulatory and commercialization milestones for ex-Asia rights to its oral type 2 diabetes drug imeglimin. Read More
The Dow plummeted a whopping 1,175 points last Monday, the largest single points drop on record, which played havoc with all sector equities. Although recovering back about half of the loss the following trading day, nervous investors were preparing for the worse - an extended turbulent period on the capital markets leading to a full correction of a significant 10 percent to 20 percent drop in the leading stock market indices. Read More
NEW YORK – Coming off a slower-than-usual year in biopharma M&A activity – due largely to drug pricing pressures and regulatory uncertainty, coupled with a robust financing environment – many industry observers have tagged 2018 to be a busy year in acquisitions. Read More
HONG KONG – Sanofi Pasteur Ltd. is taking a stand for itself amid a controversy that has quickly become a legal battle. The Public Attorney's Office of the Philippines (PAO) is taking legal action against Sanofi over the controversy surrounding the dengue vaccine Dengvaxia. Read More
LONDON – Shield Therapeutics plc is regrouping following a surprise setback, with its oral iron replacement therapy Feraccru failing in a U.S phase III trial in the treatment of anemia in chronic kidney disease (CKD) patients. Read More
Evolus Inc., of Irvine, Calif., closed its IPO of 5 million shares of common stock at $12 each, for $60 million in gross proceeds. Evolus has granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock at the same price. Read More
